Skip to main content

Table 3 Synergy experiments with PI-resistant cell lines

From: Targeting phosphoglycerate dehydrogenase in multiple myeloma

 

NCT-503

Cells

Proteosome inhibitor

IC50 of PI

Fold change in IC50

P value

-

NCT

 + 

NCT

INA6-res

CTR

Carf

3.6

3.2

0.89

0.1404

BTZ

22.7

15.0

0.66

 < 0.0001

CR

Carf

12.0

7.0

0.58

 < 0.0001

BTZ

46.6

25.8

0.55

 < 0.0001

BR

Carf

3.2

2.9

0.91

0.268

BTZ

59.0

34.3

0.58

 < 0.0001

AMO1-res

CTR

Carf

2.4

2.2

0.92

0.1998

BTZ

24.4

7.2

0.30

 < 0.0001

CR

Carf

711.0

645.0

0.91

0.1521

BTZ

199.0

113.0

0.57

 < 0.0001

BR

Carf

25.0

27.0

1.08

0.4697

BTZ

1111.0

581.0

0.52

 < 0.0001

  1. INA6-res and AMO1-res cells were treated with 1/3 of their corresponding IC50 of NCT-503 (NCT), in combination with either carfilzomib (Carf) or bortezomib (BTZ). The table summarizes the proteasome inhibitors’ (PI) IC50 values obtained from the graphs shown in Additional file 3: Fig. S3a, b.